Schrödinger, Inc. (NASDAQ:SDGR – Get Free Report) gapped down before the market opened on Thursday after Citigroup lowered their price target on the stock from $39.00 to $37.00. The stock had previously closed at $25.26, but opened at $22.90. Citigroup currently has a buy rating on the stock. Schrödinger shares last traded at $23.71, with a volume of 391,654 shares traded.
Several other equities research analysts also recently weighed in on SDGR. TD Cowen started coverage on shares of Schrödinger in a research report on Friday, January 26th. They issued an “outperform” rating and a $42.00 target price for the company. The Goldman Sachs Group lowered their price target on Schrödinger from $29.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, March 1st. Bank of America dropped their price target on Schrödinger from $38.00 to $32.00 and set a “neutral” rating on the stock in a research report on Thursday, February 29th. Piper Sandler decreased their price objective on shares of Schrödinger from $60.00 to $50.00 and set an “overweight” rating for the company in a report on Thursday, February 29th. Finally, KeyCorp dropped their target price on shares of Schrödinger from $38.00 to $33.00 and set an “overweight” rating on the stock in a report on Thursday, February 29th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $42.80.
Read Our Latest Analysis on SDGR
Insider Buying and Selling
Hedge Funds Weigh In On Schrödinger
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC lifted its holdings in Schrödinger by 8.4% in the 4th quarter. SG Americas Securities LLC now owns 5,125 shares of the company’s stock valued at $183,000 after acquiring an additional 397 shares during the last quarter. Spire Wealth Management lifted its stake in Schrödinger by 66.7% during the third quarter. Spire Wealth Management now owns 1,000 shares of the company’s stock valued at $28,000 after purchasing an additional 400 shares during the last quarter. Motley Fool Asset Management LLC boosted its holdings in Schrödinger by 2.0% during the third quarter. Motley Fool Asset Management LLC now owns 29,402 shares of the company’s stock worth $831,000 after buying an additional 570 shares in the last quarter. Tudor Investment Corp Et Al grew its position in Schrödinger by 1.0% in the third quarter. Tudor Investment Corp Et Al now owns 91,725 shares of the company’s stock worth $2,593,000 after buying an additional 908 shares during the last quarter. Finally, Perigon Wealth Management LLC increased its holdings in shares of Schrödinger by 14.1% in the third quarter. Perigon Wealth Management LLC now owns 7,811 shares of the company’s stock valued at $221,000 after buying an additional 964 shares in the last quarter. 79.05% of the stock is owned by institutional investors.
Schrödinger Stock Performance
The business has a 50-day moving average price of $26.23 and a 200 day moving average price of $28.23.
Schrödinger (NASDAQ:SDGR – Get Free Report) last announced its earnings results on Wednesday, February 28th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.12. The company had revenue of $74.10 million during the quarter, compared to analysts’ expectations of $79.12 million. Schrödinger had a negative net margin of 75.94% and a negative return on equity of 29.25%. The business’s revenue for the quarter was up 30.5% on a year-over-year basis. During the same period last year, the company posted ($0.39) earnings per share. Sell-side analysts forecast that Schrödinger, Inc. will post -2.73 earnings per share for the current fiscal year.
Schrödinger Company Profile
Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.
Featured Articles
- Five stocks we like better than Schrödinger
- Where to Find Earnings Call Transcripts
- MarketBeat Week in Review – 4/29 – 5/3
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Schrödinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Schrödinger and related companies with MarketBeat.com's FREE daily email newsletter.